Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban for VTE Prevention in Grade 4 Glioma
NCT05683808Phase 2Recruiting
- Sponsor
- University of Vermont Medical Center
- Start
- Jan 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apixaban in venous thromboembolism (VTE), sponsored by University of Vermont Medical Center. Primary endpoint: Safety of apixaban (bleeding risk) at 6 months. Started Jan 2023; status: recruiting.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT05683808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05683808.